
Craig Alan Hoover
- Assistant Clinical Professor, Medicine - (Clinical Series Track)
- (520) 626-8927
- Sarver Heart Center, Rm. 2301
- cahoover@arizona.edu
Biography
Craig A. Hoover, MD, is a Clinical Assistant Professor of Medicine at the University of Arizona College of Medicine - Tucson, Division of Cardiology. Dr. Hoover is board certified in Cardiovascular Diseases and Interventional Cardiology. He joined UArizona and BUMC in 2021 with more than 20 years of experience practicing interventional cardiology in Tucson.
Dr. Hoover received his Bachelor of Science degree in Biological Sciences from Stanford University. He was awarded his Doctorate of Medicine from Columbia University College of Physicians and Surgeons. After returning to San Francisco for his Residency in Internal Medicine, he completed his Fellowship in Cardiovascular Diseases at the University of Arizona, Tucson. He joined the University of Arizona and Southern Arizona VA Medical Center as a faculty member before going into private practice. After 15 years with Pima Heart, he joined the Carondelet Heart and Vascular Institute where he held both clinical and administrative positions before returning to his academic roots at the University of Arizona.
Dr. Hoover is a Fellow of the American College of Cardiology and the Society for Cardiovascular Angiography and Interventions. He has been active in post-graduate education and advocacy throughout his career. He served as Governor of the Arizona Chapter of the American College of Cardiology and he sat on the National Board of Governors with the ACC from 2013-2016. He has been named a Castle Connolly Top Doctor in Interventional Cardiology since 2016. His clinical intersts and expertise focus on innovative catheter-based approaches to ischemic heart disease as well as fostering a comprehensive team-based approach to deliver high quality patient care. Dr. Hoover is available to see patients in both inpatient and outpatient settings at Banner University Medical Center, Banner North Campus, Ina & Shannon and Sunrise locations.
Degrees
- M.B.A. MBA
- Eller College of Management, University of Arizona, Tucson, Arizona, United States
- M.D. Doctor of Medicine
- College of Physicians & Surgeons, Columbia University, New York, New York
- B.S. Biological Sciences
- Stanford University, Stanford, California
Work Experience
- Banner University Medical Center (2021 - Ongoing)
- St. Mary's Hospital (2019 - 2021)
- St. Mary's Hospital (2018 - 2020)
- St. Mary's Hospital (2016 - 2018)
- Carondelet Medical Group / Tenet Physician Resources (2014 - 2021)
- Tucson Medical Center (2013 - 2014)
- Tucson Heart Hospital (2011 - 2012)
- Northwest Medical Center (2008 - 2010)
- Northwest Medical Center (2008 - 2010)
- Northwest Medical Center (2004 - 2006)
- Northwest Medical Center (2004 - 2006)
- Carondelet - Saint Mary's Hospital (1999 - 2021)
- Northwest Hospital (1999 - 2016)
- Pima Heart Physicians (1999 - 2014)
- Tucson Heart Hospital (1999 - 2011)
- Southern Arizona VA Medical Center (1998 - 1999)
- Southern Arizona VA Medical Center (1997 - 1999)
- University Medical Center (1996 - 2005)
- Southern Arizona VA Medical Center (1996 - 1999)
- Southern Arizona VA Medical Center (1996 - 1999)
- Southern Arizona VA Medical Center (1996 - 1999)
Awards
- Top Doctor 2024
- Castle Connolly, Summer 2024
- Top Doctor 2023
- Castle Connolly, Summer 2023
- Top Doctor 2021
- Castle Connolly, Summer 2021
- Top Doctor 2020
- Castle Connolly, Summer 2020
- Top Doctor 2019
- Castle Connolly, Summer 2019
- Top Doctor 2018
- Castle Connolly, Summer 2018
- Top Doctor 2017
- Castle Connolly, Summer 2017
- Top Doctor 2016
- Castle Connolly, Summer 2016
Licensure & Certification
- Arizona Medical License, Arizona Medical Board (1994)
- Interventional Cardiology Certification, American Board of Internal Medicine (2000)
- Cardiovascular Disease Certification, American Board of Internal Medicine (1997)
- Internal Medicine Certification, American Board of Internal Medicine (1992)
Interests
Teaching
Clinical Decision Making, Lifelong Learning and Professional Development
Research
Clinical trials focused on novel interventional devices and therapiesEconomic and clinical outcome measures
Courses
No activities entered.
Scholarly Contributions
Journals/Publications
- Frey-Hewitt, B., Hoover, C. A., Stefanick, M. L., Terry, R. E., & Wood, P. R. (2006). The Effect of Active Weight Loss Achieved by Dieting versus Exercise on Postheparin Hepatic and Lipoprotein Lipase Activity. Annals of the New York Academy of Sciences. doi:10.1111/j.1749-6632.1987.tb36230.x
- Hoover, . A., Carmichael, . K., Nolan, . E., & Marcus, . I. (1996). Cardiac Arrest Associated With Combination Cisapride and Itraconazole Therapy. Journal of cardiovascular pharmacology and therapeutics, 1(3), 255-258.More infoWe report a case of cardiac arrest associated with cisapride in combination with itraconazole and provide a brief review of pertinent literature. Cisapride (Propulsid; Janssen Pharmaceuticals, Titusville, NJ), a gastrointestinal prokinetic drug, has recently been reported to prolong the QT interval. Itraconazole, an oral antifungal agent, is an inhibitor of cytochrome P450 (CYP3A4) metabolism and may elevate serum drug levels of compounds metabolized by this pathway. A 31-year-old woman had a witnessed cardiac arrest while taking the combination of cisapride and itraconazole. Following resucitation, the prolonged QT interval returned to normal after withdrawal of both agents. Echocardiography and cardiac catheterization were within normal limits; electrophysiologic testing failed to induce ventricular tachycardia/ventricular fibrillation. She has had no documented arrhythmias since the arrest. This combination can now be added to a growing list of drugs that may cause torsades de pointes and sudden cardiac death.
- Bigger, J. T., Hoover, C. A., Steinman, R. C., Rolnitzky, L. M., & Fleiss, J. L. (1990). Autonomic nervous system activity during myocardial ischemia in man estimated by power spectral analysis of heart period variability. The Multicenter Study of Silent Myocardial Ischemia Investigators. The American journal of cardiology, 66(4), 497-8.
- Teirstein, P. S., Hoover, C. A., Ligon, R. W., Giorgi, L. V., Rutherford, B. D., McConahay, D. R., Johnson, W. L., & Hartzler, G. O. (1989). Repeat coronary angioplasty: efficacy of a third angioplasty for a second restenosis. Journal of the American College of Cardiology, 13(2), 291-6.More infoTo determine the efficacy of repeat percutaneous transluminal coronary angioplasty, 74 patients were studied who underwent a third angioplasty for a second restenosis of one coronary artery segment. The procedure was successful in 93% of patients. Procedural complications included emergency bypass surgery (three patients) and in-hospital death (two patients). At late follow-up (mean 18 months, range 7 to 49), 30 patients (43%) had a third restenosis treated with either a fourth angioplasty (16 patients), coronary bypass surgery (11 patients) or medical management (1 patient). Thirty-nine patients (57%) had no restenosis on the basis of follow-up angiography or absence of symptoms previously attributed to restenosis. Factors associated with a third restenosis included a shorter time interval (less than 3 months) between previous angioplasty procedures and dilation of the left anterior descending coronary artery. Among the 16 patients undergoing a fourth angioplasty for a third restenosis, the procedural success rate was 94%. One patient required emergency bypass surgery. At late follow-up (mean 16 months, range 7 to 38), eight patients (53%) had a fourth restenosis treated with either a fifth angioplasty (one patient), bypass surgery (five patients) or medical management (two patients). Considering all 74 patients undergoing a third angioplasty for a second restenosis, 27% had bypass surgery, 5% died, 4% were managed medically and 64% were free of angina at late follow-up after either a third, fourth or fifth angioplasty. Restenosis rates after a third or fourth angioplasty procedure for recurrent restenosis are higher than those for the initial procedures.(ABSTRACT TRUNCATED AT 250 WORDS)